Published in Ann N Y Acad Sci on December 01, 2008
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Astrocytes in Alzheimer's disease. Neurotherapeutics (2010) 1.47
Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain (2010) 1.44
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem (2011) 1.29
The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci (2011) 1.26
NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal (2010) 1.22
Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol (2013) 1.21
Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am J Pathol (2010) 1.13
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem (2010) 1.09
The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem (2014) 1.06
Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One (2011) 1.06
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis (2014) 1.04
Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci (2013) 1.00
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease. Int J Mol Sci (2012) 0.96
Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis. EBioMedicine (2015) 0.94
Beneficial network effects of methylene blue in an amnestic model. Neuroimage (2010) 0.94
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) (2012) 0.92
Recent advances in the application of metabolomics to Alzheimer's Disease. Biochim Biophys Acta (2013) 0.92
Cerebral energy metabolism and the brain's functional network architecture: an integrative review. J Cereb Blood Flow Metab (2013) 0.92
Age-dependent roles of peroxisomes in the hippocampus of a transgenic mouse model of Alzheimer's disease. Mol Neurodegener (2013) 0.92
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol (2013) 0.91
Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci Lett (2016) 0.91
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis (2015) 0.90
Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review. Eur Neuropsychopharmacol (2014) 0.90
Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Sci Rep (2011) 0.89
Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab (2013) 0.89
Why is the neural control of cerebral autoregulation so controversial? F1000Prime Rep (2014) 0.89
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
Negative regulation of 26S proteasome stability via calpain-mediated cleavage of Rpn10 subunit upon mitochondrial dysfunction in neurons. J Biol Chem (2013) 0.88
Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology (2010) 0.87
On cognitive ecology and the environmental factors that promote Alzheimer disease: lessons from Octodon degus (Rodentia: Octodontidae). Biol Res (2016) 0.87
Selective oestrogen receptor modulators differentially potentiate brain mitochondrial function. J Neuroendocrinol (2012) 0.86
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res (2012) 0.86
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine (2015) 0.86
Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model. Front Cell Neurosci (2015) 0.83
Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Mol Cell Proteomics (2015) 0.82
Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement Geriatr Cogn Disord (2012) 0.82
Distinct pools of non-glycolytic substrates differentiate brain regions and prime region-specific responses of mitochondria. PLoS One (2013) 0.81
The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy. J Biol Chem (2015) 0.81
Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta (2016) 0.80
Benzoyl chloride derivatization with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in biological samples. J Chromatogr A (2016) 0.80
Translational potential of astrocytes in brain disorders. Prog Neurobiol (2015) 0.80
Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. Int J Alzheimers Dis (2010) 0.79
The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury. Front Mol Neurosci (2016) 0.79
Amyloid β 1-42 induces hypometabolism in human stem cell-derived neuron and astrocyte networks. J Cereb Blood Flow Metab (2015) 0.79
Amino acids variations in amyloid-beta peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease. J Bioenerg Biomembr (2009) 0.79
Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein. Cell Mol Life Sci (2015) 0.78
Electroacupuncture Upregulates SIRT1-Dependent PGC-1α Expression in SAMP8 Mice. Med Sci Monit (2015) 0.78
Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. Eur J Nucl Med Mol Imaging (2011) 0.78
Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease. Front Aging Neurosci (2015) 0.78
Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol (2010) 0.78
Regional, kinetic [(18)F]FDG PET imaging of a unilateral Parkinsonian animal model. Am J Nucl Med Mol Imaging (2013) 0.78
Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E ɛ4 Carriers. J Alzheimers Dis (2016) 0.78
Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells. Sci Rep (2015) 0.78
Posterior Cingulate Lactate as a Metabolic Biomarker in Amnestic Mild Cognitive Impairment. Biomed Res Int (2015) 0.77
OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. Neurodegener Dis Manag (2012) 0.77
Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77
The plasma membrane redox enzyme NQO1 sustains cellular energetics and protects human neuroblastoma cells against metabolic and proteotoxic stress. Age (Dordr) (2011) 0.77
Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dement Geriatr Cogn Dis Extra (2015) 0.77
Altered whole-brain white matter networks in preclinical Alzheimer's disease. Neuroimage Clin (2015) 0.77
The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. Oxid Med Cell Longev (2016) 0.77
Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. Neuropsychiatr Dis Treat (2015) 0.77
Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease. Neurol Sci (2011) 0.77
Metabolic Characterization of Intact Cells Reveals Intracellular Amyloid Beta but Not Its Precursor Protein to Reduce Mitochondrial Respiration. PLoS One (2016) 0.76
Glucose regulates amyloid β production via AMPK. J Neural Transm (Vienna) (2015) 0.76
Effects of a dietary ketone ester on hippocampal glycolytic and TCA cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer's disease. J Neurochem (2017) 0.76
Glial Na(+) -dependent ion transporters in pathophysiological conditions. Glia (2016) 0.75
Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging. Front Cell Neurosci (2017) 0.75
Cytochrome b5 reductase, a plasma membrane redox enzyme, protects neuronal cells against metabolic and oxidative stress through maintaining redox state and bioenergetics. Age (Dordr) (2015) 0.75
Exercise Counteracts Aging-Related Memory Impairment: A Potential Role for the Astrocytic Metabolic Shuttle. Front Aging Neurosci (2016) 0.75
Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease. PLoS One (2017) 0.75
Differential Fasting Plasma Glucose and Ketone Body Levels in GHRKO versus 3xTg-AD Mice: A Potential Contributor to Aging-Related Cognitive Status? Int J Endocrinol (2017) 0.75
PATHOBIOLOGY OF NEURODEGENERATION: THE ROLE FOR ASTROGLIA. Opera Med Physiol (2016) 0.75
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Front Neurosci (2016) 0.75
Imaging Reactive Oxygen Species-Induced Modifications in Living Systems. Antioxid Redox Signal (2016) 0.75
Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy. Mol Neurobiol (2016) 0.75
Energy crisis precedes global metabolic failure in a novel Caenorhabditis elegans Alzheimer Disease model. Sci Rep (2016) 0.75
Nutritional Ketosis Affects Metabolism and Behavior in Sprague-Dawley Rats in Both Control and Chronic Stress Environments. Front Mol Neurosci (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A (1993) 13.27
The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem (1977) 11.55
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Mild cognitive impairment. Lancet (2006) 10.21
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol (1979) 5.83
Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping. Science (1996) 5.40
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Life and death of neurons in the aging brain. Science (1997) 4.52
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
The neural basis of functional brain imaging signals. Trends Neurosci (2002) 4.01
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 3.49
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology (1996) 3.29
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet (1996) 2.95
Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol (1995) 2.95
Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol (2006) 2.55
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians. Arch Neurol (2000) 2.35
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol (2003) 2.26
Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology (2005) 2.24
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
New frontiers in Alzheimer's disease genetics. Neuron (2001) 2.17
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci (2003) 2.14
Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry (1999) 2.14
Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.11
Relation between physiological function and energy metabolism in the central nervous system. J Neurochem (1977) 2.08
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology (2004) 2.07
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
Advances in the early detection of Alzheimer's disease. Nat Med (2004) 1.97
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol (1996) 1.83
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain (2002) 1.81
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr (1983) 1.77
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry (2007) 1.68
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol (1990) 1.62
Cortical abnormalities in Alzheimer's disease. Ann Neurol (1984) 1.57
Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem (1997) 1.51
Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem (2003) 1.51
The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain (1998) 1.49
Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett (1995) 1.44
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol (1999) 1.35
Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage (2003) 1.33
Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med (1996) 1.18
The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci (2000) 1.16
4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience (1997) 1.13
Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord (2000) 1.10
Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab (1991) 1.06
Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid. J Neurosci Res (2003) 1.06
Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer's disease. J Clin Endocrinol Metab (1997) 1.04
Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res (1999) 1.03
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging (2005) 1.03
Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol (1994) 1.00
Altered glucose metabolism in the hippocampal head in memory impairment. Neurology (1998) 1.00
Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain (1995) 0.99
A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem (2000) 0.96
Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging (2002) 0.94
Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease. Free Radic Biol Med (2002) 0.91
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2007) 0.89
Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology (1986) 0.89
Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology (1989) 0.87
Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab (2003) 0.86
In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (1999) 0.86
Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism. J Am Geriatr Soc (1976) 0.84
Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. Am J Psychiatry (1999) 0.84
Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology (1989) 0.84
Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci (2001) 0.82
Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging (1980) 0.81
Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer disease. Int J Neurosci (1993) 0.78
Cerebral glucose metabolism in dizygotic twin pairs discordant for Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.77
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. Am Heart J (2005) 2.04
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J (2013) 1.58
Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction. Eur J Nucl Med Mol Imaging (2011) 1.47
Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling. J Nucl Cardiol (2008) 1.42
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging (2015) 1.41
Feasibility of an accurate assessment of myocardial salvage by comparing functional and perfusion abnormalities in post-reperfusion gated SPECT. J Nucl Cardiol (2010) 1.38
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord (2006) 1.25
(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med (2007) 1.23
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol (2009) 1.10
Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med (2004) 1.07
PET/CT in diagnosis of movement disorders. Ann N Y Acad Sci (2011) 1.05
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging (2005) 1.03
Kinetic parameter estimation from renal measurements with a three-headed SPECT system: a simulation study. IEEE Trans Med Imaging (2004) 1.03
Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging (2009) 0.96
Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol Aging (2011) 0.94
Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Res (2004) 0.94
PET positivity with bone marrow biopsy revealing sarcoidosis in a patient in whom bone marrow metastases had been suspected. Br J Haematol (2008) 0.93
Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. J Nucl Med (2004) 0.93
Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson's disease. J Nucl Med (2002) 0.92
Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT. J Nucl Med (2005) 0.92
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med (2008) 0.91
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med (2002) 0.90
Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol (2002) 0.89
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2007) 0.89
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging (2010) 0.88
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis. J Med Chem (2010) 0.84
Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging. PET Clin (2014) 0.84
Prognostic implications of post-stress ejection fraction decrease detected by gated SPECT in the absence of stress-induced perfusion abnormalities. Eur J Nucl Med Mol Imaging (2011) 0.82
Urinary endothelin-1 excretion according to morpho-functional damage lateralization in reflux nephropathy. Nephrol Dial Transplant (2004) 0.81
Reliability of myocardial perfusion gated SPECT for the reproducible evaluation of resting left ventricular functional parameters in long-term follow-up. Eur J Nucl Med Mol Imaging (2010) 0.81
Is 16-frame really superior to 8-frame gated SPECT for the assessment of left ventricular volumes and ejection fraction? Comparison of two simultaneously acquired gated SPECT studies. Eur J Nucl Med Mol Imaging (2008) 0.80
¹²⁵I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of αvβ₃ integrin as a molecular imaging probe for angiogenesis. J Med Chem (2012) 0.80
Relationship of infarct size and severity versus left ventricular ejection fraction and volumes obtained from 99mTc-sestamibi gated single-photon emission computed tomography in patients treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging (2004) 0.80
SPECT semiquantitative analysis of adrenocortical (131)I-6 beta iodomethyl-norcholesterol uptake to discriminate subclinical and preclinical functioning adrenal incidentaloma. J Nucl Med (2003) 0.79
Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment. J Cancer Res Clin Oncol (2012) 0.79
Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients. Eur J Nucl Med Mol Imaging (2008) 0.79
ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy. Am J Cardiol (2005) 0.78
3-Aza-6,8-dioxabicyclo[3.2.1]octanes as new enantiopure heteroatom-rich tropane-like ligands of human dopamine transporter. Bioorg Med Chem (2006) 0.78
Evaluation of the influence of age and gender on the relationships between infarct size, infarct severity, and left ventricular ejection fraction in patients successfully treated with primary percutaneous coronary intervention. J Nucl Cardiol (2010) 0.77
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. J Nucl Cardiol (2009) 0.77
Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. Eur J Nucl Med Mol Imaging (2010) 0.77
Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci (2015) 0.77
Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischarge gated SPECT. Eur J Nucl Med Mol Imaging (2007) 0.77
Predicting revascularization outcome in patients with coronary artery disease and left ventricular dysfunction (data from the SEMINATOR study). Am J Cardiol (2002) 0.76
Are there adaptive changes in the human brain of patients with Parkinson's disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT. Eur J Nucl Med Mol Imaging (2007) 0.76
Abnormal response to mental stress in patients with Takotsubo cardiomyopathy detected by gated single photon emission computed tomography. Eur J Nucl Med Mol Imaging (2010) 0.76
Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging (2013) 0.75
Use of 99mTc-sestamibi gated SPECT to assess the influence of anterograde flow before primary coronary angioplasty on tissue salvage and functional recovery in acute myocardial infarction. Eur J Nucl Med Mol Imaging (2004) 0.75
Cerebral metabolic rate of glucose quantification with the aortic image-derived input function and Patlak method: numerical and patient data evaluation. Nucl Med Commun (2016) 0.75
Assessment of the influence of atrial fibrillation on gated SPECT perfusion data by comparison with simultaneously acquired nongated SPECT data. J Nucl Med (2008) 0.75
Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system. Tumori (2006) 0.75
SBP ratio in exercise stress testing: validation by perfusion imaging. J Cardiovasc Med (Hagerstown) (2013) 0.75
Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem (2009) 0.75
Gated SPECT evaluation of the relationship between admission troponin I, myocardial salvage, and functional recovery in acute myocardial infarction treated by abciximab and early primary angioplasty. J Nucl Med (2004) 0.75
Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor. Rev Recent Clin Trials (2007) 0.75
Influence of the postexercise acquisition delay on the detection of functional abnormalities in sestamibi-gated SPECT. J Nucl Cardiol (2007) 0.75